Raia Drogasil S.A. Total Revenue

The latest total revenue for RADLY is $45B as of June 2026. That compares with $41B in the prior-year period — up 10.9% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Raia Drogasil S.A.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, RADLY's total revenue moved from $41B to $45B — a 10.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Raia Drogasil S.A.'s operating scale or balance-sheet position.

Against Healthcare companies, RADLY currently prints $45B for total revenue, while the sector average sits near $110B. That is roughly 58.3% below the sector mean. Large gaps often invite a closer look at Raia Drogasil S.A.'s growth, margins, and balance sheet.

A total revenue figure of $45B for RADLY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting RADLY's total revenue ($45B), review year-over-year change from $41B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.